Startup profile · funding coverage
MegaRobo Technologies funding, valuation and investors
Suzhou-based robotics and AI-for-science infrastructure developer; announced nearly $200M of new financing November 18, 2026.
Verified company research · funding, investors and latest developments
Keep track of MegaRobo Technologies
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Financing (series undisclosed; near amount)
Nearly $200M (exact amount undisclosed) · November 18, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$200M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
Stage not recorded · Suzhou, China
Investors in latest funding
Other: Oman Investment Authority , CMB International , Asia Investment Capital , Granite Asia , Sinovation Ventures
Overview
MegaRobo Technologies builds robotics, scientific-laboratory automation and an AI for Science software-hardware stack. The Chinese company's November 18, 2026 20:39 ET issuer release reports 'nearly $200 million' of financing joined by Oman Investment Authority, CMB International and existing Asia Investment Capital, Granite Asia and Sinovation Ventures.
No exact financing size, round series, valuation, ownership percentages or lead investor are disclosed. The vendor claims products deployed to more than 500 institutional/industry customers and over 200 Megalaxy Lab users; these are company claims, not independent sales, customer retention or scientific performance audits.
Why MegaRobo Technologies is interesting
MegaRobo's company-issued late-November 18 release says it secured nearly $200M, but NOT an exact $200M amount or named lead. Its One Intelligence Stack aims to connect lab instruments and experiments to AI agents, creating a physical feedback loop with 500+ company-reported customers. Distinguish deployed lab automation from speculative fully autonomous scientific discoveries.
Product & use cases
Illustrative institutional laboratory workflow: configure scientific experiment goals and instrument constraints; connect compatible robots, liquid handlers and lab management software; orchestrate automated experimental tasks with human safety oversight; collect instrument readings and provenance in structured formats; feed results into AI model evaluation and next-experiment proposals. MegaRobo markets 'One Intelligence Stack' and Megalaxy Lab for this loop, but compatibility, autonomous scope, integration labor, pricing and scientific outcome reproducibility must be validated in procurement.
- Automate sample handling and experiment execution in life-sciences R&D labs
- Collect structured experiment data for iterative AI model workflows
- Manage scientific instrument and robotics workflows through software
Key facts
- November 18 late ET: company-issued release reports nearly $200M financing, exact amount and stage undisclosed.
- Participants: Oman Investment Authority, CMB International, existing Granite Asia, Sinovation Ventures and Asia Investment Capital; no lead formally disclosed.
- Vendor-reported 500+ customers and 200+ Megalaxy Lab users; not audited revenue or trial results.
- AI-for-science uses real experimental robotics; advanced autonomy and scientific discoveries require external validation.
Funding history (newest first)
Financing (series undisclosed; near amount)
2026-11-18 Nearly $200M (exact amount undisclosed)- Oman Investment Authority (participant)
- CMB International (participant)
- Asia Investment Capital (participant)
- Granite Asia (participant)
- Sinovation Ventures (participant)
Source: Read source · prnewswire.com
Competitive landscape
Edge: Positions integrated laboratory robotics, automated execution and AI/data as one workflow rather than only laboratory informatics; procurement advantage remains unproven without quantified operating outcomes.
The strongest financial question is whether physical integration, utilization and recurring software spending create sustainable margins, not a claim that AI has independently 'discovered' new drugs. The issuer says more than 500 customers and >200 Megalaxy Lab users; its current website uses a broader 880+ clients figure of potentially different scope/date, so do not imply strictly comparable datasets or independent validation.
-
Emerald Cloud Lab direct
Remote automated lab execution; compare actual experiments supported and cost.
-
Strateos direct
Cloud laboratory workflows and experiment automation, especially life-sciences R&D.
-
Automata direct
Laboratory robotics and automation hardware/platform.
-
Synthace adjacent
Software to design, automate and analyze lab experiments; robotics coverage differs.
-
Benchling adjacent
R&D informatics and data system; physical execution requires lab interfaces.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about MegaRobo Technologies
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.